The 59th Annual General Meeting of the Company is scheduled on Thursday, September 3, 2026 at 2:30 PM.

August 12, 2026 To, To, The Corporate Relations Department The Listing Department The BSE Limited The National Stock Exchange of India Limit Department of Corporate Services Exchange Plaza, Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai – 400001. Mumbai – 400051 Ref:- Scrip ID:- 500126 Ref:- Scrip Code:- PGHL Dear Sir / Madam, Sub: Annual Report and Notice calling the 59th Annual General Meeting of the Company for the Financial Year ended March 31, 2026 Please find enclosed Annual Report and Notice calling the 59th Annual General Meeting (AGM) of the Company for the Financial Year ended March 31, 2026, scheduled on Thursday, September 3, 2026 at 2:30 PM. In accordance with the Circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India, the Annual Report for the Financial Year 2025-26, including the Notice of AGM have been sent in electronic mode to Members, today, August 12, 2026, whose e-mail address is registered with the Company. A physical letter with link to the Annual Report and notice calling the 59th AGM is sent to shareholders whose email address is not updated. The copy of the Notice along with the Annual Report enclosed herewith and is also available on the Company’s website: https://www.pghealthindia.com/investors/. Further, it may be noted that shareholders who would like to express their views/have questions, may register themselves as a speaker by sending their request in advance mentioning their name, demat account number/folio number, E-mail id, mobile number at investorgrievance.im@pg.com or machado.f.1@pg.com from the date of this notice up to August 27, 2026 (5:00 p.m. IST). Those Members who have registered themselves as a speaker will only be allowed to express their views/ask questions during the AGM. The Company reserves the right to restrict the number of speakers and number of questions depending on the availability of time for the AGM. Kindly take the same on record and oblige. Thanking you. For Procter & Gamble Health Limited Flavia Machado Authorized Signatory Procter & Gamble Health Limited Annual Report 2025-26 Content 1 About your Company 2 Meet your Board of Directors 4 Managing Director’s Statement 6 Financial Highlights 8 Director’s Report 18 Business Responsibility & Sustainability Report 43 Corporate Social Responsibility Report 49 Statement of Disclosure of Remuneration 50 Secretarial Audit Report 53 Corporate Governance Report 75 Statutory Auditor’s Report 86 Financial Statements Cautionary Statement Certain statements in this report regarding our business operations may constitute forward-looking statements. These include all statements other than statements of historical facts, including those regarding the financial position, business strategy, management plans and objectives for future operations. Forward-looking statements can be identified by words such as 'believes', 'estimates', 'anticipates', 'expects', 'intends', 'may', 'will', 'plans', 'outlook' and other words of similar meaning in connection with our future operations and financial performance. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual outcome to differ from those expressed or implied in these statements. The Company assumes no responsibility to publicly update, amend, modify or revise any forward-looking statements. About your Company The Procter & Gamble Company, US ("P&G") is a world leading multinational consumer goods Company, focused on providing trusted, branded products of superior quality, performance and value to improve the lives of its consumers around the world. Today, P&G products are sold in about 180 countries and territories throughout the world. Procter & Gamble Health Limited ("The Company") was incorporated in India as Merck Limited in 1967. P&G acquired the Company in the year 2018. Today, the Company is one of India's largest VMS Companies, manufacturing and marketing vitamins, minerals and supplements (VMS), which are products for a healthy lifestyle and improved quality of life, including Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion. Company’s trusted products are household names in India, protecting and supporting millions of people at every stage of life. COMPANY SECRETARY SECRETARIAL AUDITOR Ms. Zeal Rupani Dholakia & Associates LLP Company Secretaries STATUTORY AUDITOR COST AUDITOR Haribhakti & Co. LLP Joshi Apte & Associates Chartered Accountants Cost Accountants LISTED ON STOCK EXCHANGES PLANT LOCATION National Stock Exchange of Plant No. 11/1, Usgaon, Ponda, India Limited Goa – 403 407 BSE Limited REGISTERED OFFICE REGISTRAR & SHARE TRANSFER AGENT Procter & Gamble Health Limited Kfin Technologies Limited P&G Plaza, Cardinal Gracias Road, Chakala, Selenium Tower B, Plot 31-32 Andheri (E), Mumbai – 400099 Financial District, Nanakramguda Phone: +91 22 6866 9000 Serilingampally Mandal Investor Grievance Cell: 8291902520 Hyderabad, Telangana – 500 032 Website: www.pghealthindia.com Toll Free No: 1-800-309-4001 Email: investorgrievance.im@pg.com Email: einward.ris@kfintech.com Website: www.kfintech.com Annual Report 2025-26 1 MEET THE BOARD Clockwise: Ms. Seema Sambasivan, Mr. Aalok Agrawal, Mr. Milind Thatte, Mr. Shashank Srowthy, Mr. Sharad Tyagi, Ms. Krishna Sarma, Mr. S. Madhavan 2 Annual Report 2025-26 Mr. S. Madhavan Mr. Aalok Agrawal Chairperson and Independent Director Non-Executive Director Mr. S. Madhavan is a Chartered Accountant and holds Mr. Aalok Agrawal is a Bachelor of Science (Physics) a Master's Degree in Business Administration from and an MBA from Indian Institute of Management, the Indian Institute of Management, Ahmedabad, Ahmedabad. He has been with P&G for 27 years with India. He has around 39 years of experience in leadership experience on consumer healthcare & Accountancy, Economics, Finance, Law, Informations FMCG businesses and deep mastery in diverse OTC Technology, Human Resources, Risk Management value creation business models. He has worked and Business Management. He is a Director on the in diverse cultural contexts across the globe. He Boards of several prominent companies in India. is currently Sr. Vice President & General Manager, Consumer Healthcare for the Asia-Pacific, India, Middle-East & Africa region. Ms. Krishna Sarma Independent Director Ms. Seema Sambasivan Ms. Krishna Sarma is a lawyer with 31 years of Non-Executive Director experience. She is the founder and Managing Partner of Corporate Law Group. Her practice areas Ms. Seema Sambasivan holds a Master’s degree include domain expertise in the life sciences sector in Science (Microbiology) from the University of – biopharmaceuticals, medical devices, diagnostics, Mumbai. She has been with P&G for over 30 years animal drugs, and food – in the intersection between and has specialized in the health care category. law, regulatory and policy. She was the Additional She is currently the Senior Director for Personal Advocate General for the State of Assam in the Health Care – Global Product Stewardship across Supreme Court of India (2011 - 2016) and the Standing Africa, Middle East, Asia‐Pacific and China. Over Counsel for the State of Assam (2001-2016). the last 21 years, she has focused on Regulatory Affairs and leads a team across the region, delivering compliance strategies for Business and Mr. Sharad Tyagi Innovation. Her experience encompasses a wide Independent Director portfolio including medicines, supplements, food and cosmetics across diverse categories including, Mr. Sharad Tyagi is a Mechanical Engineer from Delhi Respiratory, Nerve Care, Anaemia, Energy & Muscle College of Engineering and has a Post Graduate Health, Digestive Wellness and Oral Care. Diploma in Management from Indian Institute of Management, Ahmedabad. Mr. Tyagi retired as Managing Director of Boehringer Ingelheim Mr. Shashank Srowthy India, after a 11 years’ stint, in Dece [Showing first 8,000 characters — download PDF for full document]